<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055858</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10171</org_study_id>
    <nct_id>NCT03055858</nct_id>
  </id_info>
  <brief_title>AMPLATZER Duct Occluder II Additional Sizes</brief_title>
  <acronym>ADO II AS</acronym>
  <official_title>AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ADO II AS Study is a single arm, prospective, multicenter, nonrandomized, open-label
      study to characterize the safety and effectiveness of the ADO II AS device in patients with a
      patent ductus arteriosus (PDA). Subjects will be implanted with the ADO II AS device using a
      transcatheter femoral vessel approach under fluoroscopic and echocardiographic guidance.

      To account for subject dropout, up to 50 subjects will be enrolled in this clinical
      investigation. The clinical investigation will be conducted at up to 10 centers in the United
      States.

      Subjects participating in this clinical investigation will be followed for 3 years. The
      expected duration of enrollment is 18 months. The total duration of the clinical
      investigation is expected to be 4.5 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>ADO II AS device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Endpoint: The rate of major complications after an attempted ADO II AS device implant</measure>
    <time_frame>Through 180 days</time_frame>
    <description>The rate of major complications after an attempted ADO II AS device implant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness Endpoint: The rate of effective closure of the ductus arteriosus among subjects with a successful ADO II AS implant as assessed by the presence of either a Grade 0 or Grade 1 shunt by transthoracic echocardiography.</measure>
    <time_frame>At the six-month follow-up</time_frame>
    <description>The rate of effective closure of the ductus arteriosus among subjects with a successful ADO II AS implant as assessed by the presence of either a Grade 0 or Grade 1 shunt by transthoracic echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obstruction in left pulmonary artery or aorta: The rate of significant obstruction of the pulmonary artery or aorta</measure>
    <time_frame>Through 6 month follow-up visit</time_frame>
    <description>The rate of significant obstruction of the pulmonary artery or aorta.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>PDA closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ADO II AS (PDA closure)</intervention_name>
    <description>Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).</description>
    <arm_group_label>PDA closure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of a PDA

          -  PDA ≤ 4mm in diameter

          -  PDA ≥ 3mm in length

          -  Subject (or legally authorized representative) is willing to comply with all
             pre-procedure, post-procedure, and follow-up testing requirements and provides consent
             to participate in the clinical study

        Exclusion Criteria:

          -  Weight &lt; 700 grams at time of the procedure

          -  Gestational age &lt; 24 weeks at birth

          -  Age &lt; 3 days at time of procedure

          -  Coarctation of the aorta

          -  Left pulmonary artery stenosis

          -  Cardiac output that is dependent on right to left shunt through the patent ductus
             arteriosus due to pulmonary hypertension

          -  Intracardiac thrombus

          -  Active infection requiring treatment at the time of implant

          -  Female subjects of child bearing potential are either pregnant or desire to become
             pregnant within six months post implant

          -  Other disease process likely to limit survival to less than six (6) months

          -  Participating in another study for an investigational drug and/or device that may
             clinically interfere with this study's endpoints
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evan Zahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kimberly Behning</last_name>
    <phone>651-756-5622</phone>
    <email>kbehning@sjm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maren Wagner</last_name>
    <phone>651-756-5585</phone>
    <email>mwagner2@sjm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Chang</last_name>
      <phone>424-315-2297</phone>
      <email>jennifer.chang3@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Evan Zahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arnold Palmer Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Cowden</last_name>
      <phone>321-841-5365</phone>
      <email>amanda.cowden@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>David Nykanen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Sullivan</last_name>
      <phone>313-745-1023</phone>
      <email>nsulliva@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Forbes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Allen</last_name>
      <phone>314-454-6147</phone>
      <email>allen_m@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Toby Rockefeller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Chisolm</last_name>
      <phone>614-722-4829</phone>
      <email>joanne.chisolm@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Darren Berman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Martino</last_name>
      <phone>267-426-3159</phone>
      <email>martinoo@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Gillespie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LeBonheur Children's Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth McKinney</last_name>
      <phone>206-987-3839</phone>
      <email>elizabeth.mckinney@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDA, ADO II AS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

